Back to Search Start Over

Relationship between the prevalence of subclinical tenosynovitis and treatment in patients with RA in clinical remission: STARTER study.

Authors :
Parisi, Simone
Zanetti, Anna
Carrara, Greta
Scirè, Carlo Alberto
Iagnocco, Annamaria
Filippou, Georgios
Investigators, the STARTER
Source :
Rheumatology. Apr2023, Vol. 62 Issue 4, p1485-1492. 8p.
Publication Year :
2023

Abstract

Objective This study is a sub-analysis from the patient cohort of the STARTER (Sonographic Tenosynovitis Assessment in RheumaToid arthritis patiEnts in Remission) study. The aim was to evaluate differences in ultrasound-detected joint and/or tendon involvement between patients receiving therapies based on a combination of conventional synthetic DMARDs (csDMARDs) and biologic DMARDs (bDMARDs) and those who were treated with either csDMARDs or bDMARDs in monotherapy. Material and methods Four hundred and twenty-seven consecutive patients with a diagnosis of RA were recruited between October 2013 and June 2014. They were divided into three subgroups based on their therapy at baseline: patients with bDMARD in monotherapy, patients with csDMARD in monotherapy and patients in combination therapy (csDMARD + bDMARD). At baseline, 6 months and 12 months, a clinical examination (28 joint count) and an ultrasound evaluation were performed in each patient. A score of grey-scale (GS) and power Doppler (PD) synovitis and tenosynovitis was calculated based on the OMERACT scoring systems. Results Two hundred and fifty-six patients completed the observation period: 48 patients from the bDMARD group (18.75%), 152 patients from the csDMARD group (59.38%) and 56 patients from csDMARD + bDMARD group (21.88%). The analysis showed that GS tenosynovitis and PD tenosynovitis are better controlled in combination therapy than they are with csDMARD alone (P  = 0.025 and P  = 0.047, respectively); for PD synovitis, there was a better response in those who were treated with the combination therapy when compared with the patients receiving csDMARD (P  = 0.01) or bDMARD (P  = 0.02) alone. Conclusions The analysis showed a lower prevalence of subclinical inflammatory manifestations detected with ultrasound imaging in those patients treated with the combination therapy than in those in monotherapy. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14620324
Volume :
62
Issue :
4
Database :
Academic Search Index
Journal :
Rheumatology
Publication Type :
Academic Journal
Accession number :
162940923
Full Text :
https://doi.org/10.1093/rheumatology/keac518